Abstract
Background: Diabetic nephropathy (DN) is one of the foremost causes of mortality in diabetic patients as a result of increased urinary albumin excretion (UAE) rate and compromised renal function.
Introduction: Determination of increased excretion of albumin in urine chiefly attribute to the onset and progression of DN. However, due to certain limitations of albuminuria, the search for more sensitive, specific and reliable renal biomarkers is required for early prediction of DN.
Methods: Bibliographic investigation was made to scrutinize the data reporting relevant biomarkers associated with DN and may be used to predict the onset and progression of nephropathy.
Result and Conclusion: Optimization of biomarkers for a clinical situation requires a prospective validation in large numbers of patients with diabetic nephropathy and needs to be performed in different critically ill populations.
Keywords: Albuminuria, biomarkers, diabetic nephropathy, diagnostic method, emerging biomarkers, albumin.
Current Diabetes Reviews
Title:Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy
Volume: 13 Issue: 6
Author(s): Lalit Kishore, Navpreet Kaur and Randhir Singh*
Affiliation:
- M.M. College of Pharmacy, Maharishi Markandeshwar University, Mullana-Ambala, Haryana 133207,India
Keywords: Albuminuria, biomarkers, diabetic nephropathy, diagnostic method, emerging biomarkers, albumin.
Abstract: Background: Diabetic nephropathy (DN) is one of the foremost causes of mortality in diabetic patients as a result of increased urinary albumin excretion (UAE) rate and compromised renal function.
Introduction: Determination of increased excretion of albumin in urine chiefly attribute to the onset and progression of DN. However, due to certain limitations of albuminuria, the search for more sensitive, specific and reliable renal biomarkers is required for early prediction of DN.
Methods: Bibliographic investigation was made to scrutinize the data reporting relevant biomarkers associated with DN and may be used to predict the onset and progression of nephropathy.
Result and Conclusion: Optimization of biomarkers for a clinical situation requires a prospective validation in large numbers of patients with diabetic nephropathy and needs to be performed in different critically ill populations.
Export Options
About this article
Cite this article as:
Kishore Lalit , Kaur Navpreet and Singh Randhir*, Distinct Biomarkers for Early Diagnosis of Diabetic Nephropathy, Current Diabetes Reviews 2017; 13 (6) . https://dx.doi.org/10.2174/1573399812666161207123007
DOI https://dx.doi.org/10.2174/1573399812666161207123007 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Management of Primary Aldosteronism: Its Complications and Their Outcomes After Treatment
Current Vascular Pharmacology Aldose Reductase Inhibition: Emerging Drug Target for the Treatment of Cardiovascular Complications
Recent Patents on Cardiovascular Drug Discovery Identification of Novel Anti-inflammatory Agents from Ayurvedic Medicine for Prevention of Chronic Diseases: “Reverse Pharmacology” and “Bedside to Bench” Approach
Current Drug Targets Hydroximic Acid Derivatives: Pleiotropic Hsp Co-Inducers Restoring Homeostasis and Robustness
Current Pharmaceutical Design Lipid-lowering Therapy in the Diabetic Foot: Seeing the Whole Iceberg and not Just the Tip
Current Vascular Pharmacology L-Arginine Availability as a Pathological Mechanism in Essential Hypertension, Chronic Renal and Heart Failure
Vascular Disease Prevention (Discontinued) Renoprotection by Direct Renin Inhibition: A Review Article and Meta-Analysis
Current Vascular Pharmacology CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Diabetes, Cognitive Function, and the Blood-Brain Barrier
Current Pharmaceutical Design Mitochondria as a Therapeutic Target in Alzheimers Disease and Diabetes
CNS & Neurological Disorders - Drug Targets Membrane Permeable Lipophilic Cations as Mitochondrial Directing Groups
Current Topics in Medicinal Chemistry Mechanistic Insights Into Diabetes Mellitus and Oxidative Stress
Current Medicinal Chemistry Should Percutaneous Coronary Intervention be the Standard Treatment Strategy for Significant Coronary Artery Disease in all Octogenarians?
Current Cardiology Reviews Urotensin II: Molecular Mechanisms of Biological Activity
Current Protein & Peptide Science Role of Renin Angiotensin System Inhibitors in Cardiovascular and Renal Protection: A Lesson from Clinical Trials
Current Pharmaceutical Design Treatment of Hypertension in Chronic Kidney Disease: Does one Size Fit All? A Narrative Review from a Nephrologist’s Perspective
Current Hypertension Reviews Autocrine and Paracrine Secretion of Vascular Endothelial Growth Factor in the Pre-Hypoxic Diabetic Retina
Current Diabetes Reviews NFAT Gene Family in Inflammation and Cancer
Current Molecular Medicine Treatment of Cardiovascular Calcification in Uremia
Current Vascular Pharmacology Definition of Postprandial Lipaemia
Current Vascular Pharmacology